As per the recently published report by MarketsandMarkets™, The report “HLA Typing Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User (Hospital, Diagnolab, Academia) & Region – Global Forecast to 2028″, is projected to reach USD 2.1 billion by 2028 from an estimated value of USD 1.4 billion in 2022, at a CAGR of 6.5% during the forecast period.
Download PDF Brochure: –https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=39129877
Browse
- 180 Market Data Tables
- 37 Figures
- 223 Pages and in-depth TOC on “ HLA Typing Market – Global Forecast to 2028”
Some of the prominent key players are:
- Bio-Rad Laboratories, Inc. (US),
- F. Hoffmann-La Roche Ltd. (Switzerland),
- QIAGEN N.V. (Netherlands),
- Thermo Fisher Scientific Inc. (US),
- bioMérieux S.A. (France) and many more……
Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the HLA Typing Market.
Request Sample Pages: –https://www.marketsandmarkets.com/requestsampleNew.asp?id=39129877
- Based on technology, the HLA typing market is segmented into molecular assay technologies and non-molecular assay technologies. The molecular assay technologies segment accounted for the largest market share in 2022.
- Molecular assay techniques are used in HLA typing for applications such as donor-recipient cross-matching, cancer and autoimmune disease diagnostics, infectious disease diagnostics, and transfusion.
- Based on application, the diagnostic applications market is segmented into donor-recipient match, Cancer Diagnosis and prevention, Infectious and non-infectious disease testing, Transfusion Therapy and Others. The diagnostic applications segment accounted for the highest CAGR of 6.5% during the forecast period.
- Based on the region, the HLA Typing Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America accounted for the largest share of the HLA Typing Market.
Recent Developments:
- In March 2023, BioRad received The company received AOAC International and AFNOR approval for its iQ-Check kits, which are used with the CFX Opus Deepwell Real-time PCR System
- In August 2022 Roche developed a new digital Light cycler system that helps determine a patient’s cancer.
- In May 2022, CareDx received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT software. These AlloSeq are used in patients who have received Hematopoietic cell transplantation.
The HLA Typing industry’s evolution is an exciting journey, with advancements in technology and increasing awareness of the vital role it plays in diagnostics and transplant medicine. This market’s growth is not just a statistic; it represents the potential to improve patient care and save lives, making it an integral part of the healthcare landscape. Stay tuned for more updates as we continue to track the growth and development of this dynamic industry.
